PolyPeptide follows an integrated approach to the management of environmental, social, and governance (ESG) topics that are considered material for its business. As a contract development and manufacturing organization (CDMO) serving pharma and biotech customers, PolyPeptide must adhere to stringent product quality requirements and regulations to protect the safety of patients. The Group seeks to promote corporate responsibility and to follow fundamental principles of business ethics and compliance to drive sustainable value creation for all stakeholders.
PolyPeptide believes that the integration of material ESG topics into its strategy, operations, and enterprise risk management framework is the most effective way to meet its business needs and stakeholder expectations. It uses a set of quantitative metrics to manage relevant ESG impacts, risks, and opportunities, and to track its impact and progress on sustainable development.
For further information regarding PolyPeptide’s strategy, market, and business model, see section Strategy.
This Corporate Responsibility Report covers the period from 1 January 2024 to 31 December 2024 (unless otherwise stated) and will be updated annually. It has been prepared in accordance with art. 964b of the Swiss Code of Obligations (CO) concerning transparency on non-financial matters (see section 5 Disclosures in accordance with art. 964b Swiss Code of Obligations) and with reference to the GRI Standards (see section 7 GRI content index). In accordance with the Swiss Ordinance on Climate Disclosure, this report includes the Group’s first Climate Report based on the Taskforce on Climate-related Financial Disclosure (TCFD) recommendations (see section Climate Report).
During 2024, PolyPeptide began preparing for the enhanced disclosure requirements for the financial year 2025 under the Corporate Sustainability Reporting Directive of the European Union (CSRD) and the European Sustainability Reporting Standards (ESRS). The preparations for these enhanced disclosure requirements are ongoing at the Group level with the intention of incorporating such requirements in future applicable Corporate Responsibility Reports.
The Group participates in the Carbon Disclosure program (CDP), scoring a “B” rating1 in 2024, and improving for the third consecutive year versus the “B-” rating achieved in 2023 (2022: C). This is complemented by the EcoVadis ratings, where PolyPeptide received an “Advanced”2 rating for its carbon management program, in 2024 and a “Bronze” rating for its ESG program.